Such systems would allow simultaneous assessment of GAL’s impact on tumor cell chemosensitivity and neuronal viability, better reflecting clinical scenarios where neurotoxicity is a limiting factor in chemotherapy. This evidence concerns the gene GAL and neoplasm.